X
KEY SERVICES
Details:
Ethypharm has acquired the exclusive rights for the development, registration and commercialization in the top 5 European markets of a novel celecoxib formulation already approved in the US for the acute treatment of migraine. Celecoxib is developed by Dr Reddy's.
Lead Product(s): Celecoxib
Therapeutic Area: Neurology Product Name: Elyxyb
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 19, 2021
Details:
Triamcinolone Hexacetonide is a longest-acting corticosteroid for intra articular injection. The companies have agreed to a small upfront fee along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medexus Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 18, 2020
Details:
The collaboration is intended to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.
Lead Product(s): Fentanyl
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Reading Scientific Services
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the word. 
